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Anemia is common among patients with lung cancer (1,2). Patients 
with lung cancer have the highest incidence of anemia among patients 
with solid tumors. Frequency and severity of anemia depend on tumor 
stage, duration of the cancer and intensity of anticancer therapy. 
Cancer-related anemia can be caused by myelosuppressive chemo-
therapy and radiotherapy, tumor involvement of the bone marrow, 
relative deﬁciency of erythropoietin, inappropriate response of the bone 
marrow, functional iron deﬁciency, nutritional deﬁciencies, bleeding, 
hemolysis, cytokines and other factors (1,2). A special type of cancer-
related anemia is the anemia of chronic disease which is due to mainly 
an impaired bone marrow response to erythropoietin and partly a rela-
tive inadequacy of erythropoietin production. 
Anemia leads to a wide range of symptoms, impairs health-related 
quality of life, might delay cancer therapy or even affect its outcome 
(1). The severity of symptoms depends on the absolute Hb level, the 
rapidity of onset, compensatory mechanisms, co-morbidity and other 
factors. In patients with lung cancer, the symptoms of anemia are often 
enhanced by diminished pulmonary function and other co-morbidities. 
Adequate assessment of anemia should focus on its symptoms and 
severity, laboratory ﬁndings including storage iron as well as vitamin 
levels, impact on activities of daily living, and potential causes. Multi-
dimensional instruments such as the Linear Analog Scale Assessment 
(LASA) and the Functional Assessment of Cancer Therapy-Anemia 
(FACT-Anemia) scales allow a more detailed assessment of the impact 
of anemia on quality of life. Anemic patients with lung cancer also 
have an increased risk of death. 
Treatment of anemia should attempt to correct the cause of anemia. 
Symptomatic treatment includes red blood cell (RBC) transfusions and 
the use of erythropoiesis stimulating agents (ESAs). 
RBC transfusions result in immediate but often only transient improve-
ment of anemia-related symptoms. Transfusions are of greater clinical 
relevance in lung cancer than in other cancers. Patients usually receive 
transfusions when the Hb levels drop below 10 g/dl or even 8 g/dl. This 
practice results in insufﬁcient treatment of anemia in many patients. 
ESAs (epoetin alfa, epoetin beta, darbepoetin alfa) increase or maintain 
Hb levels, decrease RBC transfusions, reduce anemia-related symp-
toms and improve overall quality of life (3). In lung cancer, the clinical 
beneﬁts of ESAs have been demonstrated for patients undergoing 
chemotherapy or chemoradiotherapy (for review see ref. 4).
Several practice guidelines have been published (5, 6). According to the 
practice guidelines of the American Society of Clinical Oncology and 
the American Society of Hematology (5), epoetins are recommended as 
a treatment option for patients with chemotherapy-associated anemia 
and a Hb concentration that has declined to a level equal to or less than 
10 g/dl, but the use of red blood cell transfusions is also considered 
a treatment option depending on the severity of anemia or clinical 
circumstances. For patients with declining Hb levels but less severe 
anemia (those with hemoglobin >12 g/dl but who have never fallen 
below 10 g/dl), the decision whether to use epoetin immediately or to 
wait until Hb levels fall closer to 10 g/dl should be determined by clini-
cal circumstances and red blood cell transfusion is also a therapeutic 
option when warranted by severe clinical conditions. 
Treatment with ESAs is usually well tolerated (3, 4, 7 - 9). Side ef-
fects include hypertension and thromboembolic events. ESAs increase 
the risk of hypertension by 1.25-fold and the risk of thromboembolic 
events by 1.67-fold (7). However, each of these side effects occurs in 
fewer than 10% of the patients. Other occasional side effects are skin 
reactions, cephalea and inﬂuenza-like symptoms. The development of 
anti-erythropoietic antibodies or pure red cell aplasia is not a problem 
in patients with cancer.
Because anemia contributes to tumor hypoxia, erythropoietic protein-
mediated control of anemia could improve tumor hypoxia and, thereby, 
improve both response to chemotherapy or radiotherapy which then 
could translate into improved survival. 
Previous randomized trials suggested that ESAs might result in im-
proved survival in anemic patients undergoing chemotherapy (8, 9). 
Two subsequent trials in patients with metastatic breast cancer undergo-
ing chemotherapy and in patients with head-and-neck cancer under-
going radiotherapy indicated a shorter survival for patients receiving 
ESAs (10, 11). Thus concerns about the safety of ESAs were raised 
and were further substantiated by the demonstration of erythropoietin 
receptors on the surface of tumor cells. However, the recent meta-anal-
ysis did not prove a detrimental effect of ESAs on survival (HR 1,08, 
95% CI 0,99-1,18) (7). Two recent trials reported a neutral effect of 
ESAs on survival and conﬁrmed the safety of ESAs in anemic patients 
undergoing chemotherapy (12, 13). One of these trials (BRAVE trial) 
assessed epoetin beta in patients with metastatic breast cancer undergo-
ing chemotherapy (12) and the other trial studied the impact of darbe-
poetin alfa on survival of patients with extensive disease of small-cell 
lung cancer undergoing palliative platinum-based chemotherapy (13). 
Based on the currently available data, several pre-cautions with regard 
to the use of ESAs should be taken. Firstly, ESAs should be used 
according to published guidelines for patients with chemotherapy-in-
duced anemia. Secondly, treatment with ESAs should aim at a target 
Hb level of 12 g/dl. Thirdly, the use of ESAs in non-anemic cancer 
patients and in anemic patients not receiving chemotherapy is not rec-
ommended. Finally, the role of erythropoetin receptors has to be further 
studied. However, all these precautions should not result in withholding 
ESAs in patients with chemotherapy-induced anemia for whom both 
the clinical beneﬁt and safety of ESAs have been demonstrated. 
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Open issues with regard to the clinical use of erythropoietic growth fac-
tors include starting Hb threshold, characterization of responders or non-
responders, the role of iron supplementation and the impact of costs. 
In summary, anemia is of major clinical relevance in patients with lung 
cancer and its management according to published practice guidelines 
will beneﬁt many patients with lung cancer.
References 
1. Pirker R et al. Am J Cancer 2005, 4, 233 
2. Groopman JE, Itri LM. J Natl Cancer Inst 1999, 91, 1616 
3. Seidenfeld J et al. J Natl Cancer Inst 2001, 93, 1204
4. Pirker R et al. Clin Lung Cancer 2003, 5, 90 
5. Rizzo JD et al. J Clin Oncol 2002, 20, 4083 
6. Bokemeyer C et al. Eur J Cancer 2004,40, 2201
7. Bohlius J et al. J Natl Cancer Inst 2006, 98, 708
8. Vansteenkiste J et al. J Natl Cancer Inst 2002, 94, 1211,
9. Littlewood TJ et al. J Clin Oncol 2001, 19, 2865 
10. Leyland-Jones B et al. J Clin Oncol 2005, 23, 5960 
11. Henke M et al. Lancet 2003, 362, 1255
12. Aapro M et al. San Antonio Breast Cancer Symposium 2006 
13. Pirker R et al. WCLC 2007
E10-02 Comprehensive Symptom Mgmt in Advanced LC, Tue, Sept 4, 16:00 – 17:30
Neurotoxicity
Cavaletti, Guido 
Univ Milano Bicocca DNTB, Monza, Italy
The peripheral nervous system is frequently the site of the toxic action 
of several drugs. The target of drug-induced neurotoxicity is mostly 
dependent on the type of substance which can act predominantly on the 
nerve ﬁbers (axon or myelin) or on the neuronal body (motoneurons 
or dorsal root ganglia primary sensory neurons). Accordingly, also 
the clinical features of drug-induced neuropathy are dependent on the 
type of agent involved, ranging from predominantly motor, to almost 
exclusively sensory or sensory-motor neuropathies, with or without 
any clinical evidence of autonomic impairment. On clinical grounds, 
several classes of very effective drugs induce sensory and/or motor 
impairment during chemotherapy or even after treatment withdrawal, 
depending on the target and site of the neurotoxic action. 
The features of the neurotoxic drugs currently involved in the treatment 
of lung cancer or with a possible future indication will be reviewed. 
Among the platinum compounds with well-established clinical use, 
cisplatin is the most severely neurotoxic. Platinum drugs appear to 
affect primarily the sensory neurons in the dorsal root ganglia where no 
blood-brain barrier is present. Cisplatin-induced neuropathy is sensory, 
predominantly characterized by symptoms of large myelinated ﬁbre 
damage, such as numbness and tingling, paresthesias of the upper and 
lower extremities, reduced vibration and position sense perception, 
reduced deep tendon reﬂexes, and incoordination with gait disturbance. 
After completion of cisplatin chemotherapy only a part of the patients 
has signiﬁcant neurotoxic symptoms, whereas 3-4 months later the 
proportion is deﬁnitely higher (the “coasting” phenomenon). Conven-
tional dosages of carboplatin have been associated with a lower risk of 
peripheral neuropathy than cisplatin. Besides chronic sensory neurotox-
icity, in about 90% of patients oxaliplatin treatment has been associated 
with acute neurosensory toxicity, including dysesthesia and paresthesia.
Several putative neuroprotective agents (i.e. Org2766, reduced gluta-
thione, nerve growth factor, BNP7787, acetyl-L-carnitine, xaliproden, 
vitamin E, ...) are currently undergoing pre-clinical and/or clinical 
investigation.
The antitubulin drugs are among the most promising agents for the 
current and future treatment of cancer, since not only are they already 
part of well-established chemotherapy schedules, but also several new 
drugs are currently in the pre-clinical phase or are in phase-I/II clinical 
development. At present, two families of antitubulin agents, acting with 
opposite mechanisms of action, are widely used to treat cancer: the 
taxanes and the vinca alkaloids. Among the taxanes, paclitaxel is more 
neurotoxic than docetaxel but in both cases neurotoxicity may be dose-
limiting. The clinical features of the peripheral neurotoxicity induced 
by taxanes are qualitatively identical, and they are mostly represented 
by distal, symmetrical hypoesthesia in the upper and lower extremi-
ties with a length-dependent distribution. In most cases, all sensory 
modalities are affected and deep tendon reﬂex loss is an early feature of 
taxanes’ peripheral neurotoxicity. Motor signs and symptoms can occur 
during treatment with paclitaxel or docetaxel, although only rarely 
is motor impairment a clinically-relevant feature. Very rarely distal 
neuropathic pain may ensue during taxane treatment, while myalgia 
is a frequent symptom. The signs of taxanes’ peripheral neurotoxicity 
tend to be reversible but, in a minority of cases, persistence of sensory 
impairment is observed and incomplete recovery can occur.
Neuroprotective strategies have been tested using Org2766, glutamine, 
leukaemia inhibitor factor, acetyl-L-carnitine and BNP7787.
Most of the patients treated with vincristine develop dose-dependent 
potentially treatment-limiting neurotoxicity with the clinical features 
of a sensorimotor peripheral neuropathy caused by inhibition of 
anterograde and retrograde axonal transport secondary to microtubule 
damage. Sensory signs and symptoms are predominant in the major-
ity of the patients, with distal symmetrical hypoesthesia and dyses-
thesia involving all the sensory modalities (i.e. deep and superﬁcial), 
sometimes with a painful component. Muscular cramps can occur, in 
association with reduced strength in the distal muscles, in the most 
severely affected patients. Severe impairment of motor function leading 
to tetraplegia has occasionally been described in children or in patients 
with pre-existing hereditary neuropathies. Similarly, there have been 
occasional reports of isolated peripheral nerve functional impairment. 
Rarely, the “coasting” phenomenon has been described also with vin-
cristine. Autonomic nervous system involvement is observed in about 
one third of the subjects exposed to vincristine presenting with ortho-
static hypotension, urinary bladder dysfunction and erectile impotence. 
However, the most severe clinical occurrence is constipation due to a 
paralytic ileus or megacolon. The toxic signs induced by vincristine 
are reversible in most cases, but long-lasting impairment or incomplete 
recovery are frequent.
Neuroprotection with insulin-like growth factor-1 (IGF-1) has been 
achieved in one of the several animal models developed to investigate 
vincristine peripheral neurotoxicity, but no data in humans have so far 
been reported.
Among newly-developed antitubulin substances, epothilones have 
aroused considerable excitement, being extremely active as a microtu-
bule stabilizer, with an effect which is the same as that observed with 
taxanes. Given the common mechanism of action, it is not surprising 
that epothilones, similarly to taxanes, can induce dose-limiting periph-
eral neurotoxicity. However, the data available so far do not make it 
possible to have a clear picture of the clinical presentation of epothi-
lone-induced nerve impairment and no conclusive data are available on 
the time course of epothilone-induced neuropathy or on its site of ac-
